Shi Yuankai
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 (NCT04999800) | Shi Yuankai | 2021-07-18 |
| Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China (NCT04740996) | Shi Yuankai | 2021-02-04 |
| SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma (NCT03744208) | Shi Yuankai | 2018-12-30 |
Track Shi Yuankai automatically
Every clearance here is in the API, with alerts when new ones post.